It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).
Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).
Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with mannitol (low certainty).
Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).
Dornase alfa showed no clear difference in number of people experiencing exacerbations ‐ at 3 months compared with mannitol (low certainty).
Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa showed no clear difference in number of people experiencing exacerbations at 3 months compared with dornase alfa and mannitol (low certainty).